D
Dean J. Kereiakes
Researcher at University of California, San Francisco
Publications - 507
Citations - 47173
Dean J. Kereiakes is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Myocardial infarction & Percutaneous coronary intervention. The author has an hindex of 95, co-authored 473 publications receiving 44314 citations. Previous affiliations of Dean J. Kereiakes include Seton Medical Center.
Papers
More filters
Journal ArticleDOI
ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina)
Eugene Braunwald,Elliott M. Antman,John W. Beasley,Robert M. Califf,Melvin D. Cheitlin,Judith S. Hochman,Robert H. Jones,Dean J. Kereiakes,Joel Kupersmith,Thomas N. Levin,Carl J. Pepine,John W. Schaeffer,Earl E. Smith,David E Steward,Pierre Theroux,Raymond J. Gibbons,Joseph S. Alpert,David P. Faxon,Valentin Fuster,Gabriel Gregoratos,Loren F. Hiratzka,Alice K. Jacobs,Sidney C. Smith +22 more
TL;DR: The present guidelines supersede the 1994 guidelines and summarize both the evidence and expert opinion and provide final recommendations for both patient evaluation and therapy.
Journal ArticleDOI
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
Jeffrey W. Moses,Martin B. Leon,Jeffrey J. Popma,Peter J. Fitzgerald,David R. Holmes,Charles O'Shaughnessy,Ronald P. Caputo,Dean J. Kereiakes,David O. Williams,Paul S. Teirstein,Judith Jaeger,Richard E. Kuntz +11 more
TL;DR: In this randomized clinical trial involving patients with complex coronary lesions, the use of a sirolimus-eluting stent had a consistent treatment effect, reducing the rates of restenosis and associated clinical events in all subgroups analyzed.
Journal ArticleDOI
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Laura Mauri,Dean J. Kereiakes,Robert W. Yeh,Priscilla Driscoll-Shempp,Donald E. Cutlip,P. Gabriel Steg,P. Gabriel Steg,Sharon-Lise T. Normand,Eugene Braunwald,Stephen D. Wiviott,David J. Cohen,David R. Holmes,Mitchell W. Krucoff,James B. Hermiller,Harold L. Dauerman,Daniel I. Simon,David E. Kandzari,Kirk N. Garratt,David P. Lee,Thomas K. Pow,Peter Ver Lee,Michael J. Rinaldi,Joseph M. Massaro,Joseph M. Massaro +23 more
TL;DR: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding.
Journal ArticleDOI
ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article
Eugene Braunwald,Elliott M. Antman,John W. Beasley,Robert M. Califf,Melvin D. Cheitlin,Judith S. Hochman,Robert H. Jones,Dean J. Kereiakes,Joel Kupersmith,Thomas N. Levin,Carl J. Pepine,John W. Schaeffer,Earl E. Smith,David E Steward,Pierre Theroux,Raymond J. Gibbons,Joseph S. Alpert,David P. Faxon,Valentin Fuster,Gabriel Gregoratos,Loren F. Hiratzka,Alice K. Jacobs,Sidney C. Smith +22 more
TL;DR: These revised guidelines for the management of unstable angina and non–ST-segment elevation myocardial infarction were published in September 2000 and the present article describes these revisions and provides further updates in this rapidly moving field.
Journal ArticleDOI
Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention: REPLACE-2 Randomized Trial
A. Michael Lincoff,John A. Bittl,Robert A. Harrington,Frederick Feit,Neal S. Kleiman,J. Daniel Jackman,Ian J. Sarembock,David J. Cohen,Douglas Spriggs,Ramin Ebrahimi,Gadi Keren,Jeffrey Carr,Eric A. Cohen,Amadeo Betriu,Walter Desmet,Dean J. Kereiakes,Wolfgang Rutsch,Robert G. Wilcox,Pim J. de Feyter,Alec Vahanian,Eric J. Topol +20 more
TL;DR: Bivalirudin with provisional Gp IIb/IIIa blockade is statistically not inferior to heparin plus planned Gp IIIa blockade during contemporary PCI with regard to suppression of acute ischemic end points and is associated with less bleeding.